RhoC is essential for TGF-β1-induced invasive capacity of rat ascites hepatoma cells

Biochemical and Biophysical Research Communications

Volumn 346, Issue 1, 2006, Pages 74-82

  Mukai, M ^a   Endo, H ^a   Iwasaki, T ^b   Tatsuta, M ^a   Togawa, A ^c   Nakamura, H ^a   Inoue, M ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^c RIKEN Center for Biosystems Dynamics Research   (Japan)

Author keywords

Invasion; RhoA; RhoC; TGF 1

Indexed keywords

PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOC PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES HEPATOMA; CANCER INVASION; CELL MIGRATION; CONTROLLED STUDY; GENETIC TRANSFECTION; HEPATOMA CELL; MALE; MOLECULAR CLONING; NONHUMAN; PERITONEUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; CELLS, CULTURED; GENE EXPRESSION PROFILING; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; NEOPLASM INVASIVENESS; RATS; RHO GTP-BINDING PROTEINS; RHOA GTP-BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33744992232     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.05.068     Document Type: Article

References (39)

1. Blobe G.C., Schiemann W.P., and Lodish H.F. Role of transforming growth factor beta in human disease. N. Engl. J. Med. 342 (2000) 1350-1358
2. Derynck R., Akhurst R.J., and Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat. Genet. 29 (2001) 117-129
3. Mukai M., Shinkai K., Komatsu K., and Akedo H. Potentiation of invasive capacity of rat ascites hepatoma cells by transforming growth factor-β. Jpn. J. Cancer Res. 80 (1989) 107-110
4. Farina A.R., Coppa A., Tiberio A., Tacconelli A., Turco A., Colletta G., Gulino A., and Mackay A.R. Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int. J. Cancer 75 (1998) 721-730
5. Platten M., Wick W., Wild-Bode C., Aulwurm S., Dichgans J., and Weller M. Transforming growth factors β(1) (TGF-β(1)) and TGF-β(2) promote glioma cell migration via Up-regulation of α(V)β(3) integrin expression. Biochem. Biophys. Res. Commun. 268 (2000) 607-611
6. Giannelli G., Fransvea E., Marinosci F., Bergamini C., Colucci S., Schiraldi O., and Antonaci S. Transforming growth factor-β1 triggers hepatocellular carcinoma invasiveness via α3β1 integrin. Am. J. Pathol. 161 (2002) 183-193
7. Bartolome R.A., Galvez B.G., Longo N., Baleux F., Van Muijen G.N., Sanchez-Mateos P., Arroyo A.G., and Teixido J. Stromal cell-derived factor-1α promotes melanoma cell invasion across basement membranes involving stimulation of membrane-type 1 matrix metalloproteinase and Rho GTPase activities. Cancer Res. 64 (2004) 2534-2543
8. Like B., and Massague J. The antiproliferative effect of type beta transforming growth factor occurs at a level distal from receptors for growth-activating factors. J. Biol. Chem. 261 (1986) 13426-13429
9. Lee K.M., Park J., Kim J.H., Yie S.W., Chun G.T., Kim P.H., and Choi E.Y. Reorganization of myosin and focal adhesion proteins in Swiss 3T3 fibroblasts induced by transforming growth factor β. Cell Biol. Int. 23 (1999) 507-517
10. Koyasu S., Kadowaki T., Nishida E., Tobe K., Abe E., Kasuga M., Sakai H., and Yahara I. Alteration in growth, cell morphology, and cytoskeletal structures of KB cells induced by epidermal growth factor and transforming growth factor-β. Exp. Cell Res. 176 (1988) 107-116
11. Nakajima Y., Yamagishi T., Yoshimura K., Nomura M., and Nakamura H. Antisense oligodeoxynucleotide complementary to smooth muscle alpha-actin inhibits endothelial-mesenchymal transformation during chick cardiogenesis. Dev. Dyn. 216 (1999) 489-498
12. Lomri A., and Marie P.J. Effects of transforming growth factor type beta on expression of cytoskeletal proteins in endosteal mouse osteoblastic cells. Bone 11 (1990) 445-451
13. Hall A. Rho GTPases and the actin cytoskeleton. Science 279 (1998) 509-514
14. Aspenstrom P. Effectors for the Rho GTPases. Curr. Opin. Cell Biol. 11 (1999) 95-102
15. Fritz G., Just I., and Kaina B. Rho GTPases are over-expressed in human tumors. Int. J. Cancer 81 (1999) 682-687
16. del Peso L., Hernandez-Alcoceba R., Embade N., Carnero A., Esteve P., Paje C., and Lacal J.C. Rho proteins induce metastatic properties in vivo. Oncogene 15 (1997) 3047-3057
17. Stam J.C., Michiels F., van der Kammen R.A., Moolenaar W.H., and Collard J.G. Invasion of T-lymphoma cells: cooperation between Rho family GTPases and lysophospholipid receptor signaling. Embo J. 17 (1998) 4066-4074
18. Yoshioka K., Nakamori S., and Itoh K. Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. Cancer Res. 59 (1999) 2004-2010
19. Imamura F., Shinkai K., Mukai M., Yoshioka K., Komagome R., Iwasaki T., and Akedo H. Rho-mediated protein tyrosine phosphorylation in lysophosphatidic-acid-induced tumor-cell invasion. Int. J. Cancer 65 (1996) 627-632
20. Mukai M., Nakamura H., Tatsuta M., Iwasaki T., Togawa A., Imamura F., and Akedo H. Hepatoma cell migration through a mesothelial cell monolayer is inhibited by cyclic AMP-elevating agents via a Rho-dependent pathway. FEBS Lett. 484 (2000) 69-73
21. Suwa H., Ohshio G., Imamura T., Watanabe G., Arii S., Imamura M., Narumiya S., Hiai H., and Fukumoto M. Overexpression of the RhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br. J. Cancer 77 (1998) 147-152
22. van Golen K.L., Wu Z.F., Qiao X.T., Bao L.W., and Merajver S.D. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 60 (2000) 5832-5838
23. Shikada Y., Yoshino I., Okamoto T., Fukuyama S., Kameyama T., and Maehara Y. Higher expression of RhoC is related to invasiveness in non-small cell lung carcinoma. Clin. Cancer Res. 9 (2003) 5282-5286
24. Horiuchi A., Imai T., Wang C., Ohira S., Feng Y., Nikaido T., and Konishi I. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab. Invest. 83 (2003) 861-870
25. Clark E.A., Golub T.R., Lander E.S., and Hynes R.O. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406 (2000) 532-535
26. Hakem A., Sanchez-Sweatman O., You-Ten A., Duncan G., Wakeham A., Khokha R., and Mak T.W. RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev. 19 (2005) 1974-1979
27. Bhowmick N.A., Ghiassi M., Bakin A., Aakre M., Lundquist C.A., Engel M.E., Arteaga C.L., and Moses H.L. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol. Biol. Cell 12 (2001) 27-36
28. Edlund S., Landstrom M., Heldin C.H., and Aspenstrom P. Transforming growth factor-β-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol. Biol. Cell 13 (2002) 902-914
29. Kleer C.G., van Golen K.L., Zhang Y., Wu Z.F., Rubin M.A., and Merajver S.D. Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am. J. Pathol. 160 (2002) 579-584
30. Akedo H., Shinkai K., Mukai M., Mori Y., Tateishi R., Tanaka K., Yamamoto R., and Morishita T. Interaction of rat ascites hepatoma cells with cultured mesothelial cell layers: a model for tumor invasion. Cancer Res. 46 (1986) 2416-2422
31. Masszi A., Di Ciano C., Sirokmany G., Arthur W.T., Rotstein O.D., Wang J., McCulloch C.A., Rosivall L., Mucsi I., and Kapus A. Central role for Rho in TGF-β1-induced α-smooth muscle actin expression during epithelial-mesenchymal transition. Am. J. Physiol. Renal Physiol. 284 (2003) F911-F924
32. Vardouli L., Moustakas A., and Stournaras C. LIM-kinase 2 and cofilin phosphorylation mediate actin cytoskeleton reorganization induced by transforming growth factor-β. J. Biol. Chem. 280 (2005) 11448-11457
33. Sahai E., and Marshall C.J. ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat. Cell Biol. 4 (2002) 408-415
34. Simpson K.J., Dugan A.S., and Mercurio A.M. Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma. Cancer Res. 64 (2004) 8694-8701
35. Wang L., Yang L., Luo Y., and Zheng Y. A novel strategy for specifically down-regulating individual Rho GTPase activity in tumor cells. J. Biol. Chem. 278 (2003) 44617-44625
36. Pille J.Y., Denoyelle C., Varet J., Bertrand J.R., Soria J., Opolon P., Lu H., Pritchard L.L., Vannier J.P., Malvy C., Soria C., and Li H. Anti-RhoA and anti-RhoC siRNAs Inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol. Ther. 11 (2005) 267-274
37. Muraoka R.S., Dumont N., Ritter C.A., Dugger T.C., Brantley D.M., Chen J., Easterly E., Roebuck L.R., Ryan S., Gotwals P.J., Koteliansky V., and Arteaga C.L. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109 (2002) 1551-1559
38. Lobell R.B., Omer C.A., Abrams M.T., Bhimnathwala H.G., Brucker M.J., Buser C.A., Davide J.P., deSolms S.J., Dinsmore C.J., Ellis-Hutchings M.S., Kral A.M., Liu D., Lumma W.C., Machotka S.V., Rands E., Williams T.M., Graham S.L., Hartman G.D., Oliff A.I., Heimbrook D.C., and Kohl N.E. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. 61 (2001) 8758-8768
39. Kusama T., Mukai M., Iwasaki T., Tatsuta M., Matsumoto Y., Akedo H., Inoue M., and Nakamura H. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 122 (2002) 308-317